Biology and significance of signalling pathways activated by IGF-II

DOI: 10.3109/08977194.2011.640325

Document Version
Accepted author manuscript

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Published in:
Growth Factors

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Biology and significance of signalling pathways activated by IGF-II
Lynda K Harris and Melissa Westwood
Maternal and Fetal Health Research Centre, University of Manchester, Manchester, M13 9WL, UK

Keywords: fetal growth, placenta, development, myogenesis, vasculogenesis, cancer

Corresponding author: Melissa Westwood, Maternal and Fetal Health Research Centre, University of Manchester, Manchester Academic Health Sciences Centre, St Mary’s Hospital, Oxford Road, Manchester, M13 9WL, UK. Tel: 44 (0)161-276-5460; Fax: 44 (0)161-701-6971; e-mail: melissa.westwood@manchester.ac.uk
Abstract

Insulin-like growth factor-II (IGF-II) affects many aspects of cellular function through its ability to activate several different receptors and consequently, numerous intracellular signalling molecules. Thus, IGF-II is a key regulator of normal fetal development and growth. However, abnormalities in IGF-II function are associated with cardiovascular disease and cancer. Here we review the cellular mechanisms by which IGF-II’s physiological and pathophysiological actions are exerted by discussing the involvement of the type 1 and type 2 IGF receptors (IGF1R and IGF2R), the insulin receptor and the downstream MAP kinase, PI-3 kinase and G-protein coupled signalling pathways in mediating IGF-II stimulated cellular proliferation, survival, differentiation and migration.
Introduction
IGF-II is a 67-amino acids protein produced by post-translational removal of the COOH-terminal E domain from the precursor molecule, pro-IGF-II [1]. Partial cleavage of the E domain results in big-IGF-II (2 isoforms; 1-104 or 1-87) which, along with pro-IGF-II, are also found in the circulation [2]. Mature IGF-II can itself be processed to generate des(37-40) IGF-II (also known as vesiculin; [3]). Little is known about the signalling properties and function of these IGF-II variants so this review will focus on the actions of the mature protein. IGF-II can interact with a number of cell-surface receptors (Figure 1) but it binds to the type I IGF receptor (IGF1R) with highest affinity and therefore it’s likely that this receptor mediates much of IGF-II’s effect on cellular proliferation, survival, differentiation and migration. However, IGF-I also binds to IGF1R and in general, elicits the same effects with greater potency, which has led to some speculation about the specific purpose of IGF-II. In recent years this has been clarified through the use of receptor inhibitors and a better understanding of the pathways downstream of the type 2 IGF / mannose-6-phosphate receptor (IGF2R) and also, the A isoform of the insulin receptor (IR-A; Figure 1), both of which bind IGF-II with greater affinity than IGF-I. Here we discuss aspects of physiology and pathophysiology that have been attributed to IGF-II.

Type 1 IGF receptor: IGF1R is a heterotetramer with structural homology to the insulin receptor thus in tissues that express both, many of the IGF binding sites are formed as hybrids of the two receptor types [4], though their affinity for IGF-II is similar to that of IGF1R [4]. Activation of IGF1R results in autophosphorylation of tyrosine residues in the intracellular β-subunits and then, in general, initiation of the PI-3 kinase/AKT or MAP kinase signalling cascades (reviewed in [5-7]).

Insulin receptor: The insulin receptor exists as two isoforms, IR-A and IR-B, depending on the absence or presence of exon 11 splicing [8]. IR-A, but not IR-B, has a high affinity for IGF-II and in fact, binds IGF-II just as well as IGF1R. IR-A is also linked to the same downstream signalling molecules as the classical IGF receptor but IGF-II/IR-A interactions are reported to preferentially activate the MAP kinase pathway [8].

Type 2 IGF receptor: IGF2R is structurally unrelated to either IGF1R or IR as it consists of just a single, primarily extracytoplasmic, polypeptide chain. This receptor binds IGF-II with greater affinity than IGF-I and whilst it does not accept insulin as a ligand [9], it does have high affinity for the sugar mannose-6-phosphate (M-6-P), and can therefore bind lysosomal enzymes and other growth factors and cytokines. Cloning of the type 2 IGF receptor cDNA [10] led to the realization that this receptor was also the cation independent receptor for M-6-P; given the well documented role of this receptor in the intracellular transport of lysosomal enzymes, it was suggested that rather than mediating IGF-II effects, it might be important for clearing IGF-II from the circulation. However, although IGF2R contains neither tyrosine kinase activity nor an autophosphorylation site, it does link to G-proteins which provides a mechanism for signal transduction [9].

IGF-II access to all of these receptors is controlled by a family of six highly specific binding proteins (IGFBPs 1-6), though their role in modulating IGF-II bioavailability and function is reviewed elsewhere [11-15].

Role of IGF-II and its receptors in fetal growth
It is well established that the IGF axis is essential for fetal development and growth. In humans, evidence for the importance of IGF-II comes from the observation that Igf2 is maternally imprinted [16]. Relaxation of imprinting leads to Beckwith-Wiedermann syndrome in which excess IGF-II is associated with fetal overgrowth [17]. The genes for IGF1R, IGF2R and IR are not imprinted although all three receptors are key for normal prenatal growth [18-20]. However, most of the growth disorders associated with perturbations
in the IGF axis are not due to gene defects and many studies have demonstrated that the correlation between fetal growth restriction (FGR) and decreased IGF-II levels [21-25] commonly occurs in the absence of any apparent mutation. Interestingly, not all studies report a relationship between serum IGF-II concentrations and fetal weight [26;27]. Igf2 and Igf2R are polymorphic and variants in both are associated with birth weight [19;28], which may account for these conflicting findings. Another possibility is the variation in the level of soluble IGF2R, which is formed by proteolytic cleavage in the transmembrane region of the expressed receptor [29] and is known to inhibit IGF-II’s actions [30;31]. This component of the IGF axis is rarely analysed in relation to fetal growth, however one study that IGF-II levels are associated with birth weight only when considered as a molar ratio to soluble IGF2R and that depending on parity, the IGF-II/IGF2R ratio accounted for up to 5% in birth weight variance [32].

In mice, the gene for IGF-II and that for IGF2R, which is thought to regulate the availability of IGF-II, are reciprocally imprinted [33;34], presenting an attractive mechanism for balancing the needs of mother and fetus during pregnancy [35]. Like humans, perturbations in ligand and receptor expression are associated with altered fetal growth in the mouse. Ablation of the IGF-II gene results in severe in utero growth restriction and neonatal mice which are 40% smaller than their wild type littermates [36]. In postnatal life, igf2 null animals are always remarkably smaller than their normal littermates, however their growth velocity is unaffected, which has led to the suggestion that IGF-II’s role as a growth regulator is principally relevant to fetal life. Elimination of the type 1 IGF receptor accentuates the growth-restricted phenotype (45% of normal birthweight) and results in perinatal lethality [37] whereas mice in which the Igf2r has been ablated have elevated levels of circulating IGF-II and are 25-30% larger than wild type littermates [38;39]. Unlike in humans, a null mutation in the insulin receptor gene has no affect on fetal growth [40].

**IGF-II affects fetal growth by influencing placental development and function**

IGF-II null mice and, importantly, mice lacking only the placental-specific transcript of IGF-II [41] have small placentas [42]. In contrast, animals carrying a null mutation in Igf2r, like the fetuses with Beckwith-Wiedemann syndrome, exhibit placentomegaly and, unusually [43], these placentas continue to grow right up till birth [38]. Together, these studies suggest that IGF-II may influence fetal growth by promoting normal placental development and function.

In human placenta, IGF–II is expressed by the chorionic villi (cytotrophoblasts, mesodermal core and vascular endothelium) and fetal membranes (amnion and chorion laeve) from early pregnancy [44], though the IGF-II present in the maternal circulation also has a role in regulating events within the placenta [45]. IGFI1R is apparent in trophoblast and villous endothelium and stroma [46]. This finding led to the hypothesis that a reduction in the number or distribution of placental type 1 IGF receptors might be a contributing factor in pregnancies complicated by FGR. This is supported by data from a Western blot analysis of such placentas [47], however a study using immunohistochemistry was unable to discern any differences in receptor localization or density [46], and analysis by quantitative PCR detected an increase in expression [48]. Aberrations in the signalling molecules downstream of IGFI1R (Figure 2A) could also influence placental, and consequently, fetal growth [45] and decreased expression and / or activation of Akt and members of the MAP kinase pathway in placentas from FGR pregnancies has been described [47;49].

Mice containing null mutations in both the IGF-II and IGFI1R genes were more severely growth restricted than those in which only the receptor had been ablated [42]. This, together with the fact that placental weight is reduced in IGF-II deficient mice suggests that not all of IGF-II’s effects are mediated through IGFI1R; in the human placenta, candidates include
IGF2R and the insulin receptor, both of which are expressed by trophoblast [50;51], though the distribution of the IR isoforms within placenta has not been documented.

**IGF-II influences placental development and function by a number of mechanisms**

*Trophoblast turnover:* The outer syncytiotrophoblast layer of the human placenta, which is bathed in maternal blood and is therefore crucial as an immune barrier and transporting epithelium, is a terminally differentiated cell that must be renewed and expanded by differentiation and fusion of cells from an underlying cytotrophoblast progenitor layer. Apoptotic elements are continuously shed into the maternal circulation. A role for IGF-II in regulating cytotrophoblast proliferation was implied by an immunohistochemical analysis of first trimester placenta which demonstrated a correlation between IGF-II expression and proliferative activity [52], though we have provided direct evidence using an explant model of first trimester [53] and term [54] human placenta in which IGF-II is supplied to the syncytiotrophoblast surface, mimicking exposure to hormone in the maternal circulation. In these experiments, IGF-II stimulated the proliferation of cells in the underlying cytotrophoblast layer, which suggests the presence of pathways capable of transducing signals from the syncytiotrophoblast to the cytotrophoblast; conceivably this might be achieved either by a syncytioplasmic kinase relay activated by ligand binding at the maternal-facing microvillous membrane, or by transcytosis of ligand with exocytosis at the basal syncytial surface and rebinding to receptor on cytotrophoblast. Other data supporting a role for the maternal IGF axis comes from a study of food-restricted guinea pigs in which maternal IGF-II levels were related to placental structural development[55-59].

The majority of IGF-II’s mitogenic actions are thought to be mediated through IGF1R (Figure 2A) and this is certainly supported by the studies on mice with a null mutation in this gene, as these animals have a much more severe phenotype than those lacking either of the ligands. We found that IGF-II-stimulated cytotrophoblast proliferation was reduced in the presence of a specific IGF1R inhibitor [53] however, IGF2R may also have a role in mediating IGF-II’s mitogenic effects as proliferation was enhanced in term placental explants exposed to an IGF-II analogue, Leu$^{27}$IGF-II [54]. Leu$^{27}$IGF-II primarily binds to IGF2R [60] and is commonly used to distinguish between cellular signalling and function initiated by IGF-II/IGF1R versus IGF-II/IGF2R interactions. We have shown, again by using pharmacological inhibitors, that the MAP kinase pathway is responsible for mediating the proliferative effects of IGF-II [53], thus it is interesting to note that through activation of sphingosine kinase and the production of sphingosine-1-phosphate, the ligand for G-protein coupled S1P receptors, IGF2R can also link in to this signalling cascade [61]. Flux through the MAP kinase, and other signalling pathways, is regulated by protein tyrosine phosphatases (PTPs). Although expressed by placenta [62], relatively little is known about their importance in this tissue, though we have recently found that one of the enzymes, SHP-2, is required for IGF-II stimulation of cytotrophoblast proliferation [63].

IGF-II is known to provide a survival signal in many cell systems and recent work suggests that at the maternal-fetal interface also, it may play a role in this context since it can protect both first trimester [53] and term [54] cytotrophoblast from apoptosis. IGF1R is clearly involved in mediating this effect, though downstream, the PI-3 kinase/Akt rather than the MAP kinase pathway seems to be key (Figure 2A) [53]. Again, the contribution of IGF2R must be considered; Leu$^{27}$IGF-II promoted cytotrophoblast survival however our data indicates that IGF2R also functions as a clearance receptor, since in tissue with reduced IGF2R, IGF-II activity was enhanced thereby suggesting that IGF-II signalling can be redirected through IGF1R [54].
Trophoblast migration: Successful implantation and placental development depends on adequate extravillous trophoblast invasion (EVT) of the maternal endometrium and there are several lines of evidence to implicate IGF-II as a mediator of this process. mRNA localization studies have demonstrated abundant IGF-II expression in the trophoblastic columns of the anchoring villi, particularly in those cells at the leading edge of the column [44]. Moreover, *in vitro* studies have shown that in monolayer wounding [64] or trans-Matrigel barrier assays [65], the migration of these cells is increased in response to IGF-II. Several reports suggest that IGF-II’s ability to promote migration is dependent on IGF2R [66;67] and in trophoblast also, Leu^{27}IGF-II and QAYL-Leu^{27}IGF-II, another analogue that is selective for IGF2R, enhanced migration whereas function-blocking IGF2R antibodies were inhibitory [68]. The authors also report that IGF-II signalling through this receptor involves G_{i} proteins and activation of the MAP kinase pathway [68] as well as the Rho kinases, ROCK-I and –II (Figure 2B) [69]. Members of the Rho GTPase family (RhoA and RhoC) are also required for IGF-II stimulation of EVT through IGF1R [69]. There is some controversy about the role of IR-A in mediating IGF-II directed EVT migration, as Shields and colleagues suggest from their work using an IR tyrosine kinase inhibitor, that this receptor is not involved [69], whereas a study using a choriocarcinoma cell model of EVT, found that the actions of IGF-II were reduced in the presence of a different IR inhibitor [70].

Nutrient transport: IGF-II is also a potent metabolic factor and could therefore modulate fetal growth by influencing nutrient transfer across the placenta. IGF-II is known to stimulate both glucose and amino acid uptake by cultured human trophoblast [71-74] and in the guinea pig, maternal administration of IGF–II has been shown to increase placental transport of nutrients to the fetus resulting in enhanced fetal growth [56;57;75]. Similar effects were observed when animals were treated with Leu^{27}IGF-II, suggesting that maternal IGF-II promotes, at least in part, nutrient delivery to the fetus via IGF2R [58]. Indeed, rather than a direct affect of IGF-II, enhanced nutrient transfer across an enlarged placenta has been proposed as an explanation for the increased embryo weights noted in the mice null for IGF2R [38]. Correspondingly, deletion of placental IGF-II leads to a reduction in the surface area of the nutrient exchange barrier [41;76], decreased amino acid transfer [77] and consequently, fetal growth restriction.

Role of IGF-II in early cardiac development, myogenesis and vasculogenesis
IGF-II gene expression has been reported as early as embryonic day 5.5 (E5.5) in the pre-implantation mouse blastocyst, where it is localised to the extraembryonic ectoderm and the ectoplacental cone, but not the epiblast [78]. At E6.5, *Igf2* transcripts are also expressed in the columnar visceral endoderm, extraembryonic mesoderm, and in trophoblast giant cells. At E7.5, expression is observed in all extraembryonic structures, including the allantois, the amnion, the chorion and the visceral yolk sac. At this time, *Igf2* expression is noted in a restricted region of embryonic mesoderm, which at E8.0, extends to include the developing heart, the lateral mesoderm, the head mesenchyme, and the lining of the foregut. The functional importance of IGF-II signalling during cardiac development was highlighted when the differentiation potential of murine embryonic stem (ES) cells expressing reduced levels of IGF-II was investigated: the absence of *Igf2* severely impaired the expression of mesoderm markers, and the subsequent formation of mesoderm derivatives including cardiomyocytes and muscle fibers [79]. In addition, IGF-II synthesised by the epicardium is required to activate MAP kinase signalling pathway and induce cardiomyocyte proliferation in the developing mouse heart from E10.5-E14.5. *Igf2* null mice exhibit significantly decreased rates of cardiomyocyte proliferation in the ventricular wall at E11.5, resulting in ventricular wall hypoplasia [80]. IGF-II signalling also regulates differentiation of adult myoblasts, inducing exit from the cell cycle, expression of muscle-specific genes and formation of multinucleated
myotubes. Initiation of myogenesis is achieved by an IGF-II-mediated increase in ERK5 phosphorylation and kinase activity, translocation of ERK5 to the nucleus and myogenic E box promoter activity (Figure 2B) [81].

The IGF2R signalling axis also regulates postnatal vasculogenesis by controlling homing of endothelial progenitor cells (EPC). EPC isolated from human placental cord blood express high levels IGF2R, and IGF-II signalling through IGF2R, but not IGF1R, increased EPC migration, invasion, adhesion to fibrinogen and MMP-9 secretion in vitro [82]. Signalling was mediated via the G protein subunit G(i) and phospholipase-Cβ2 (PLCβ2), leading to an increase in intracellular Ca^{2+} (Figure 2B) [82]. IGF-II promoted recruitment of murine bone marrow mononuclear cells (MBMMC) and neo-vascularisation in a mouse Matrigel plug assay, and increased the number of MBMMC incorporated into the capillaries in a mouse model of hindlimb ischemia [82].

**IGF-II signalling in cardiovascular development and disease**

Cardiomyocyte apoptosis is one of the primary causes of cardiovascular pathology following myocardial infarction. The adult cardiomyocyte cannot proliferate, thus the signalling pathways that regulate cell survival have been extensively studied. IGF-I signalling through IGF1R promotes physiological cardiac growth and function, and improves cardiac output after myocardial infarction by stimulating contractility and tissue remodelling [83]. In contrast, evidence from cell culture studies and animal models is mixed, suggesting that IGF-II signalling can induce hypertrophy, extracellular matrix remodelling and apoptosis, but also that IGF-II overexpression can enhance cardiomyocyte survival.

Treatment of the cardiomyoblast cell line H9c2 with angiotensin-II upregulated IGF-II and IGF2R expression, induced activation of caspase-8 and -9, and increased cardiomyoblast apoptosis via an IGF2R-dependent mechanism [84]. Similarly, Leu^{21}IGF-II has been shown to enhance angiotensin-II induced H9c2 cell apoptosis, mediated by the interaction of IGF2R with the G protein subunit Gαq and phosphorylation of PLCβ3, leading to increased caspase activation and DNA fragmentation (Figure 2B) [85]. These findings are mirrored in neonatal rat ventricular myocytes following knockdown of IGF1R expression, where IGF-II treatment induced phosphorylation of Akt, increased caspase-3 activation and induced apoptosis [86]. Interestingly, Leu^{21}IGF-II treatment also increased apoptosis in cells lacking IGF1R, but did so in the absence of Akt phosphorylation. Instead, activation of Gαq and calcineurin lead to translocation of the pro-apoptotic protein Bad to the mitochondria, cytochrome c release and activation of caspase-3 and -9 (Figure 2B) [86].

Signalling through IGF2R induces H9c2 cell hypertrophy, via its interaction with Gαq, and phosphorylation of protein kinase C-α and calcium/calmodulin-dependent protein kinase II, leading to increased expression of the cardiac hypertrophy markers atrial natriuretic peptide and brain natriuretic peptide (Figure 2B) [87]. IGF-II signalling through IGF2R also promoted extracellular matrix catabolism in these cells, by increasing the expression of matrix metalloproteinase-9, urokinase plasminogen activator and tissue plasminogen activator, and by reducing expression of tissue inhibitor of metalloproteinases-2 [88].

In vivo, rats subjected to ligation of the abdominal aorta exhibit increased expression of IGF-II and IGF2R in the left ventricle, and display hypertension and enhanced myocyte apoptosis [84]. As expression of IGF2R is increased in areas of infarcted human myocardium [87], and elevated expression is maintained in the resulting scar tissue [88], signalling through the IGF2R may enhance pathological myocardial apoptosis and hypertrophy, exacerbating the existing damage.

In contrast to the studies cited above, transduction of cardiomyocytes with an adenoviral vector encoding IGF-II significantly reduced apoptosis induced by heat shock or ischemia-
reoxygenation [89]. Moreover, downregulation of the IGF-II clearance receptor IGF2R in neonatal rat cardiac myocytes reduced cell susceptibility to hypoxia- and tumour necrosis factor-induced apoptosis [90]. These findings suggest that IGF-II signalling through IGF1R can enhance cardiomyocyte survival.

**IGF-II signalling in cancer**

Aberrant autocrine and paracrine IGF-II signalling, leading to enhancement of cell proliferation and resistance to apoptosis, has long been implicated in the initiation and progression of tumour growth [91]. Epigenetic alterations, such as loss of DNA imprinting, occur in cancer at least as commonly as genetic mutations. The majority of imprinted genes exist in clusters, and their expression is regulated by the methylation status of CpG-rich cis-elements, known as differently methylated regions (DMRs) [92]. The DMRs are differentially methylated on CpG sites by DNA methyltransferases, depending on the parental origin of the allele [92]. *Igf2* is an example of an imprinted gene; loss of imprinting (LOI) of the normally silent maternal allele of *Igf2* leads to overexpression of IGF-II protein and an increased risk of malignancy.

**Colon cancer:** Biallelic expression of *Igf2* in a mouse model of intestinal neoplasia induced intestinal adenoma formation, elongation of intestinal crypts and an increased population of epithelial progenitor cells in the mucosa [93]. This increase in mucosal epithelial progenitor cells is also observed in the normal gut mucosa of humans presenting with colon-specific LOI of *Igf2* [93], leading to an elevated risk of colorectal cancer for affected individuals [94]. Similar findings were observed when azoxymethane was used to induce the formation of premalignant aberrant crypt foci in mice with *Igf2* LOI: expression of proliferation-related genes in the intestinal crypts was increased, leading to enhanced tumour formation [95]. Blockade of the IGF1R signalling pathway using the competitive inhibitor NVP-AEW541 decreased expression of proliferation-related genes and significantly reduced pre-malignant aberrant crypt foci formation [95]. Using mouse embryo fibroblast cell lines from *Igf2* LOI and wild type embryos, the authors also demonstrated that LOI cells showed an enhanced sensitivity to IGF-II signalling. Low doses of IGF-II induced sustained Akt activation in LOI cells, whereas cells from wild type embryos exhibited only a transient increase in Akt activation [95]. IGF2R and insulin receptor expression were also increased in these cells.

**Breast cancer:** Female transgenic mice engineered to exhibit enhanced IGF-II expression in the mammary gland displayed an increased incidence of aggressive, metastatic, mammary tumours [96], implicating chronic IGF-II signalling as a tumourigenic stimulus. As predicted, when these animals were crossed with transgenic mice overexpressing IGF2R, their offspring exhibited a significant delay in the onset of mammary tumour formation and reduced tumour burden [97]. Biallelic IGF-II expression has been observed in human breast cancer samples: one study reported LOI in 67% of benign lesions and 60% of malignant lesions, whereas all control samples displayed normal IGF-II imprinting [98]. However, only 3 benign and 5 malignant tissue samples were analysed, so these data must be interpreted with caution. ProIGF-II has been shown to promote the survival of the MCF7 breast cancer cell line by activating PI3K/Akt signalling and upregulating the expression of the anti-apoptotic proteins Bcl-2 and Bcl-X<sub>L</sub> [99]. Mature IGF-II can also promote breast cancer progression by activating estrogen receptor-α (ER-α) and ER-β in the absence of estrogen. In breast cancer cells, IGF-II binding to IGF1R and the insulin receptor induced translocation of ER-α and ER-β to the mitochondria, facilitating activation of cell survival pathways [100].
**Pancreatic cancer:** Transgenic mice expressing the SV40 large T-antigen (Tag) under the control of the insulin gene regulatory region develop hyperplasia within the islets of Langerhans, followed by the occurrence of pancreatic tumours. Increased IGF-II expression, due to LOI of the Igf2 gene, is observed in this population of hyperproliferative β cells [101]. When crossed with Igf2 null mice, Tag mice displayed a dramatically reduced tumour burden and had a five-fold higher incidence of tumour cell apoptosis [101], again highlighting both the proliferative and pro-survival effects of IGF-II signalling. Interestingly, Tag mice that carried a disruption in either the paternal or maternal Igf2 allele developed tumours of a similar size and histology to wild type Tag mice, indicating that both the developmentally expressed paternal allele or the inactive maternal allele could contribute to tumour development [102]. In humans, evidence of a role for IGF-II in pancreatic cancer is mixed: a nested case-control study has shown no correlation between increased serum concentration of IGF-II and increased risk of pancreatic cancer [103], and no change in IGF-II mRNA expression was observed in human pancreatic cancer samples, despite biallelic Igf2 expression [104]. However, a recent study has reported hypermethylation of the Igf2 DMR2 in insulinomas, which was associated with LOI and overexpression of IGF-II at the mRNA and protein level [105].

**Lung cancer:** Immortalised mouse embryonic fibroblasts from wild-type, and but not integrin α11 null mice, significantly enhanced the growth of A549 human lung adenocarcinoma cells, when co-implanted into immune deficient mice [106]. Gene profiling of the resulting tumours revealed a 100-fold reduction in IGF-II mRNA expression in tumours formed in mice injected with the integrin α11 null fibroblasts [106]. siRNA-mediated knockdown of fibroblast IGF-II expression reduced the growth of A549 tumours to a similar extent, suggesting that in this system, the growth promoting effects of stromal fibroblasts were (i) mediated by the paracrine actions of IGF-II and (ii) dependent on fibroblast integrin α11 expression [106].

**Brain tumours:** IGF-II is overexpressed in a subset of high-grade glioblastomas that lack amplification or overexpression of the EGF receptor, and are characterised by poor survival [107]. Tumours overexpressing IGF-II were highly proliferative, exhibited enhanced Akt phosphorylation and displayed PTEN loss. IGF-II signalling through IGF1R and PI3-kinase regulatory subunit 3 recapitulated the tumourigenic effects of EGF and promoted the growth of glioblastoma-derived neurospheres *in vitro* (Figure 2B) [107].

**Other cancers:** As mentioned above, individuals with Beckwith-Wiedemann syndrome (BWS) exhibit biallelic Igf2 expression, along with aberrant expression of p57, CDKN1C, H19, and LIT1, and have an increased risk of developing childhood cancers [17]. Approximately 5–10% of BWS patients develop embryonal tumours, including Wilms’ tumour of the kidney, but they are also at increased risk of adrenocortical carcinoma, hepatoblastoma and rhabdomyosarcoma [17]. Wilms’ tumour is associated with defects in the Wil1 gene, which encodes a transcriptional repressor of Igf2, and with mutations in the 11p15.5 region that alter Igf2 imprinting. As such, biallelic Igf2 expression is observed in the majority of pathological cases [108]. Biallelic IGF-II expression has also been reported in human cases of testicular germ cell tumours [109], choriocarcinoma [110], primary lung cancers including adenocarcinoma, squamous cell carcinoma, large and small cell carcinoma [111], and cervical carcinomas [112], uterine leiomyosarcoma [113] and endometrial cancer [114].
IGF2R signalling in cancer
The tumour suppressor function of the IGF2R was first demonstrated by O’Gorman et al., who showed that down-regulation of IGF2R expression in JEG-3 choriocarcinoma cells enhanced proliferation in vitro, and increased tumor growth rate in vivo [115]. Conversely, IGF2R overexpression reduced JEG-3 cell proliferation in vitro, and decreased tumor growth in nude mice [116]. IGF2R overexpression did not alter endogenous IGF-II production, or secretion of the IGF2R ligands procathepsin D and L, but did promote secretion and activation of latent TGF-β1. Overexpression of a soluble form of the receptor dramatically reduced tumour cell growth in vitro and in vivo, but did not alter the level of TGF-β1 [116]. These data suggest that increased levels of soluble IGF2R inhibit cell proliferation.

Unlike its murine homologue, human Igf2r exhibits biallelic expression, [117;118], although a few individuals exclusively express the maternal allele [119]. Mutations in Igf2r, or loss of heterozygosity at the 6q26–27 locus where Igf2r resides, lead to reduced IGF2R expression and increased circulating concentrations of IGF-II. Loss of biallelic Igf2r expression has been reported in cancers of the breast, liver, prostate, lung, adrenal gland, head, neck and endometrium [120] and in the kidneys of Wilms tumor patients [121]. Loss of heterozygosity proximal to the Igf2r locus is also predictive of the presence of disseminated tumour cells in the bone marrow of ovarian cancer patients, before and after chemotherapy [122].

IR-A signalling in cancer
Ligation of IR-A by IGF-II initiates a proliferative response [123], and abberant IR-A signalling has been implicated in a number of diseases, including cancer (Reviewed in [8]). IGF-II signalling through IR-A has also been shown to induce differential expression of genes involved in signal transduction, cell cycle, metabolism, angiogenesis and adhesion, when compared to insulin signalling [124].

IR-A is the predominant IR isoform expressed by carcinomas of the breast, colon and lung [123], and the relative abundance of IR-A is increased in thyroid cancer, compared to normal thyroid tissue [125]. Activation of IR by IGF-II in human breast cancer cell lines stimulated proliferation, with IGF-II exhibiting 63% of the potency of insulin. In contrast, IGF-II signalling through IR in non-malignant human breast cells was less than 1% as potent as insulin [126]. IGF-II is also reported to be a more potent stimulator of SKUT-1 leiomyosarcoma cell migration than insulin, a cell line that expresses IR-A but not IGF1R [127]. However, siRNA-mediated knockdown of IR-A in SW480 human colon adenocarcinoma cells increased viability and enhanced IGF1R activation by IGF-II [128], suggesting that IGF-II bioactivity is mediated most effectively by IGF1R.

Summary
In summary, IGF-II is a critical mediator of cell fate, regulating normal embryonic development and placental function, but also inducing aberrant proliferation and cell survival in cancer and cardiovascular disease. By understanding in more detail how the actions of IGF-II are regulated, either through genetic, epigenetic or posttranslational modifications, downstream signaling cascades, or via its interactions with IGF binding proteins or the IGF-2R, we will be better placed to combat its pathophysiological effects.
**Declarations of Interest:** LKH is supported by a BBSRC David Phillips Research Fellowship. The Maternal and Fetal Health Research Centre is supported by the Manchester Academic Health Sciences Centre and the Greater Manchester Comprehensive Local Research Network.
References


[27] Osorio M, Torres J, Moya F, Pezzullo J, Salafia C, Baxter R, Schwander J, Fant M: Insulin-like growth factors (IGFs) and IGF binding proteins-1, -2, and...


[37] Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72.


[54] Harris LK, Crocker IP, Baker PN, Aplin JD, Westwood M: IGF2 actions on trophoblast in human placenta are regulated by the insulin-like growth factor 2 receptor, which can function as both a signaling and clearance receptor. Biol Reprod 2011;84:440-446.


[74] Fang J, Mao D, Smith CH, Fant ME: IGF regulation of neutral amino acid transport in the BeWo choriocarcinoma cell line (b30 clone): evidence for MAP


[86] Chu CH, Tzang BS, Chen LM, Liu CJ, Tsai FJ, Tsai CH, Lin JA, Kuo WW, 
Bau DT, Yao CH, Huang CY: Activation of insulin-like growth factor II 
receptor induces mitochondrial-dependent apoptosis through G(α)q and 
downstream calcineurin signaling in myocardial cells. Endocrinology 
2009;150:2723-2731.

[87] Chu CH, Tzang BS, Chen LM, Kuo CH, Cheng YC, Chen LY, Tsai FJ, Tsai 
CH, Kuo WW, Huang CY: IGF-II/mannose-6-phosphate receptor signaling 
induced cell hypertrophy and atrial natriuretic peptide/BNP expression via 
Galphaq interaction and protein kinase C-alpha/CaMKII activation in H9c2 

[88] Chang MH, Kuo WW, Chen RJ, Lu MC, Tsai FJ, Kuo WH, Chen LY, Wu WJ, 
Huang CY, Chu CH: IGF-II/mannose 6-phosphate receptor activation induces 
metalloproteinase-9 matrix activity and increases plasminogen activator 

[89] Su EJ, Cioffi CL, Stefansson S, Mittereder N, Garay M, Hreniuk D, Liau G: 
Gene therapy vector-mediated expression of insulin-like growth factors 
protects cardiomyocytes from apoptosis and enhances neovascularization. Am J 

[90] Chen Z, Ge Y, Kang JX: Down-regulation of the M6P/IGF-II receptor 
increases cell proliferation and reduces apoptosis in neonatal rat cardiac 


[92] Mann JR, Szabo PE, Reed MR, Singer-Sam J: Methylated DNA sequences in 

[93] Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom WS, 
Okano H, Ko MS, Ohlsson R, Longo DL, Feinberg AP: Loss of imprinting of 
Igf2 alters intestinal maturation and tumorigenesis in mice. Science 


MS, Levchenko A, Feinberg AP: Enhanced sensitivity to IGF-II signaling links 
loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc 

[96] Pravtcheva DD, Wise TL: Metastasizing mammary carcinomas in H19 

[97] Wise TL, Pravtcheva DD: Delayed onset of Igf2-induced mammary tumors in 


Figure legends

Figure 1. Affinity of IGF-II for its various receptors. IGF1R – type 1 IGF receptor; IGF2R – type 2 / mannose-6-phosphate receptor; IR – insulin receptor. The IGF1R can form hybrids with either IR-A or IR-B.

Figure 2. Signalling pathways activated following IGF-II binding to the type 1 or type 2 IGF receptor (IGF1R and IGF2R; Panel A and B respectively). PKC – protein kinase C; PLC – phospholipase C; CaMKII – Calcium/calmodulin dependent protein kinase II; MMP – matrix metalloproteinase. Leu²⁷IGF-II – IGF-II analogue that binds primarily to IGF2R; pathways identified through the use of this analogue are shown in red.
Figure 2A

IGF1R

IGF-II

IGF-II

PI-3K
Akt

cytotrophoblast survival

glioma proliferation

cytotrophoblast proliferation

MEK
ERK 1/2
Figure 2B

- IGF2R
- Leu<sup>27</sup> IGF-II
- Leu<sup>27</sup> IGF-II
- Leu<sup>27</sup> IGF-II
- IGF-II
- IGF-II

**Gα<sub>(i)</sub>**
- ERK 1/2
- ROCK-I, -II
- EVT migration
- Gα<sub>(q)</sub>
- PI-3K
- MEK
- Gα<sub>(i)</sub>

ERK 1/2:
- PKCα
- PLCβ<sub>3</sub>
- calcineurin
- caspase-3 activation
- cytochrome c release
- caspase-8, -9 activation
- cardiomyoblast apoptosis
- myocyte apoptosis
- cardiomyocyte hypertrophy

ROCK-I, -II:
- CaMKII

EVT migration:
- cardiomyoblast apoptosis

PI-3K:
- Akt
- caspase-3 activation
- myocyte apoptosis
- cardiomyoblast proliferation
- cardiomyoblast differentiation

MEK:
- ERK 1/2
- ERK 5
- myogenic E box promoter
- Ca<sup>2+</sup>
- MMP-9

Gα<sub>(i)</sub>:
- PLCβ<sub>3</sub>
- endothelial progenitor cell migration